The effect of doxycycline on atherogenesis in apoE-knockout mice

• Autorzy: Pawlowska M. , Gajda M. , Pyka-Fosciak G. , Toton-Zuranska J. , Niepsuj A. , Kus K. , Bujak-Gizycka B. , Suski M. , Olszanecki R. , Jawien J. , Korbut R.
• Języki publikacji: EN

Abstrakty

EN

Doxycycline at subantimicrobial doses inhibits matrix metalloproteinases (MMPs) activity, and is the only MMP inhibitor which is widely available in clinical practice. The aim of the study was to reveal whether non-specific MMPs inhibition by tetracycline could ameliorate development of atherosclerosis in apolipoprotein E (apoE)-knockout mice. Doxycycline (1.5 mg/ kg b.w./day) administered orally attenuated atherogenesis, measured both by "en face" method (10.25±1.7% vs. 15.7±2.0%, p<0.05) and "cross-section" method (66,254±7,468 µm2 vs. 90,687±8,521 µm2, p<0.05). In-situ zymography showed decrease of the extent of non-specific gelatinase activity in doxycycline-treated mice This is the first report to date describing the effect of doxycycline on atherogenesis in apoE-targeted mice.

Słowa kluczowe

EN

doxycycline; tetracycline; atherogenesis; apolipoprotein E; matrix metalloproteinase; cholesterol; triglyceride; extracellular matrix degradation; proteinase; endogenous inhibitor; mice; mouse; atherosclerosis

• Wydawca: -
• Czasopismo: Journal of Physiology and Pharmacology
• Rocznik: 2011
• Tom: 62
• Numer: 2
• Opis fizyczny: p.247-250,fig.,ref.

Twórcy

autor

Pawlowska M.

• Chair of Pharmacology, Jagiellonian University Medical College, 16 Grzegorzecka Street, 31-531 Krakow, Poland

autor

Gajda M.

autor

Pyka-Fosciak G.

autor

Toton-Zuranska J.

autor

Niepsuj A.

autor

Kus K.

autor

Bujak-Gizycka B.

autor

Suski M.

autor

Olszanecki R.

autor

Jawien J.

autor

Korbut R.